Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2052W HIGH $15.17
Volume
152.44 K
Value Traded
102.29 K
Short % Float
2.79%
Days to Cover
1.2
-12.62%Week
-42.49%1 Month
-73.84%3 Month
-82.09%6 Month
-99.82%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.05 M
EPS (TTM)
-2.25
P/E Ratio
-
Ent. Value
-1.09 M
Total Shares
10.10 M
Float Shares
10.10 M
Insiders
0.03%
Institutions
4.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GOVX Catalyst Timeline
Dated clinical, regulatory and corporate events for GeoVax Labs, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for GeoVax Labs, Inc.
214Total events
0Upcoming
31Tier-1 (high impact)
2007 to 2018Coverage
Event history 50
◆Trial InitiationGOVX-B11Trial
Anticipated start of additional Phase 1 trial of GOVX-B11 with protein boosts
HIV preventive (clade B)source ↗
◆Trial InitiationTrial
Expected initiation of human clinical trials for HIV functional cure combination
HIV therapeutic (functional cure)source ↗
◆Trial InitiationTrial
Expected initiation of human clinical trials for HIV therapeutic vaccine in early 2018
HIV therapeuticsource ↗
●IND SubmissionIND
AGT expected to file IND for HIV functional cure combination with GeoVax vaccine
HIV therapeutic (functional cure)source ↗
●Oral PresentationLM01Presentation
Presented updates on Lassa fever vaccine efficacy at International Society for Vaccines, Institut Pasteur Paris
Lassa feversource ↗
▲PublicationPresentation
Published findings on elicitation of broadly neutralizing antibody precursor for HIV CD4 binding site in PLOS ONE
HIV preventive (clade C)source ↗
▲PublicationZM02Presentation
Published Zika vaccine NS1 protein study in Scientific Reports
Zika virussource ↗
◆Preclinical PoCPreclinical
Initial preclinical proof-of-concept studies for malaria vaccine expected to commence in September 2017
Malariasource ↗
●Oral PresentationPresentation
Presented preliminary cancer vaccine results at Immuno-Oncology Summit and World Vaccine Congress
Cancer immunotherapy (MUC1)source ↗
▲Preclinical PoCLM01Preclinical
Single dose of GEO-LM01 provided 100% protection in murine challenge model
Lassa feversource ↗
◆Full ResultsClinical Data
Initial and confirmatory data readouts for cancer immunotherapy expected in Q3 2017
Cancersource ↗
▲Partnership / LicenseCorporate
Expanded LASV vaccine development collaboration with Scripps Research Institute
Lassa feversource ↗
▲Oral PresentationZM02Presentation
Single dose GEO-ZM02 100% protection in mice presented at ASM MICROBE 2017
Zikasource ↗
▲Preclinical PoCZM02Preclinical
Single dose of GEO-ZM02 gave 100% protection in lethal mouse challenge model
Zika virussource ↗
▲Preclinical PoCPreclinical
Zika vaccine demonstrates 100% protection in preclinical lethal challenge model
Zika Virussource ↗
▲Trial InitiationTrial
Malaria vaccine development initiated with The Burnet Institute
Malariasource ↗
▲Partnership / LicenseCorporate
Collaboration with American Gene Technologies for HIV functional cure
HIV therapeuticsource ↗
▲Trial InitiationGOVX-B11Trial
HVTN initiated Phase 1 trial HVTN 114 of GOVX-B11
HIV preventive (clade B)source ↗
◆IND SubmissionIND
AGT expected to file IND for HIV therapeutic vaccine later in 2017
HIV therapeuticsource ↗
▲Preclinical PoCPreclinical
Single dose of Ebola vaccine protected 100% of rhesus monkeys
Ebolasource ↗
▲Partnership / LicenseCorporate
Added Georgia State University and Peking University as collaborators for chronic hepatitis B therapeutic vaccine
Chronic Hepatitis Bsource ↗
▲Partnership / LicenseCorporate
Collaboration with ViaMune for co-development of cancer immunotherapy programs
cancersource ↗
◆Enrollment UpdateGOVX-B11Trial
Patient enrollment expected to begin in early November 2016 for HVTN 114
HIVsource ↗
◆Trial InitiationTrial
Additional challenge studies for tetravalent vaccine expected to commence
Hemorrhagic Fever (Ebola, Sudan, Marburg, Lassa)source ↗
▲Preclinical PoCPreclinical
Proven 100% protection in rodent and non-human primate challenge studies for Ebola vaccine; demonstrated VLP production for other individual vaccines
Hemorrhagic Fever (Ebola, Sudan, Marburg, Lassa)source ↗
◆Trial InitiationGOVX-B11Trial
HVTN to begin next clinical trial of GOVX-B11 testing protein boosts
HIV (Clade B)source ↗
●IND SubmissionGOVX-B11IND
IND application filed for GOVX-B11 preventive HIV vaccine trial HVTN 114
HIVsource ↗
▲Preclinical PoCPreclinical
Demonstrated individual vaccines produce non-infectious VLPs for each HFV target
Hemorrhagic Fever Viruses (Ebola, Sudan, Marburg, Lassa)source ↗
▲Partnership / LicenseCorporate
Collaboration with University of Georgia for Zika vaccine development
Zika virussource ↗
●Preclinical PoCPreclinical
Continued work on tetravalent hemorrhagic fever vaccine
hemorrhagic fever (Ebola, Marburg, Lassa)source ↗
◆Trial InitiationTrial
Next clinical trial for Clade B HIV vaccine expected to begin later in 2016
HIV (Clade B)source ↗
◆Timing GuidanceGOVX-E301Presentation
Epidemic-ready GOVX-E301 vaccine expected to be available by 2016
Ebola (ZEBOV strain)source ↗
◆IND SubmissionIND
IND submission for monovalent and multivalent Ebola/Marburg vaccines
Ebola/Marburg vaccinessource ↗
●Manufacturing MilestoneGOVX-E301CMC / Inspection
Production of first vaccine lot for clinical testing anticipated in 2016
Ebolasource ↗
▲Partnership / LicenseCorporate
Collaborative Research Agreement signed with University of Pittsburgh
cancersource ↗
▲Partnership / LicenseCorporate
Collaboration with University of Pittsburgh for MVA-VLP cancer immunotherapy
Cancer immunotherapysource ↗
▲Preclinical PoCPreclinical
Encouraging preclinical animal data for Ebola vaccine candidate demonstrating 100% protection in two rodent models
Ebolasource ↗
Past FDA Catalysts and PDUFA Decisions
How GOVX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 90%
Micro Cap(rank 591 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GEO-CM04S1 VaccineNCT04977024 | COVID-19 Infection | Phase 2 | ACTIVE NOT_RECRUITING | 63 | Dec 1, 2027 | ||||||
| Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 VaccineCompletedNCT04639466 | COVID-19 Infection | Phase 2 | COMPLETED | 119 | Dec 1, 2025 | ||||||
| Ad/PNP Monoclonal antibodyCompletedNCT03754933 | Recurrent Head and Neck Cancer | Phase 2 | COMPLETED | 10 | Dec 1, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every GOVX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GeoVax DNA/MVA Vaccine | HIV | Phase 2a | 2013-10-09 | 93.2% of the DDMM arm; less than 3-fold; 100% to 84%Read More | GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV New Clinical Data from HVTN 205, a Phase 2a Trial of GeoVax's Preventive HIV Vaccine, Presented at 2013 AIDS Vaccine Meeting Atlanta, GARead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SPENCER JOHN N JRDirector | Buy | 10,000 21,402 held | $0.55 | 10/17/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in GOVX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GOVX for Q2 2026. | ||||
GOVX Institutional Ownership Trends
GOVX Short Interest
Shares sold short, counted twice a month.
2.79%
Short % of Float
of tradable shares sold short
281.8K
Shares Sold Short
-43.5% vs prior count
1.2 Low
Days to Cover
trading days of normal volume to buy every short share back
241.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GOVX ranks across every disease it competes in
Competitive Position is a premium feature
See how GOVX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGOVX News
GOVXGeoVax Reports 2017 Third Quarter Financial Results a nd Development Program Update s Progress in Multiple Vaccine Programs Including HIV , Zika, Lassa Fever , Malaria, Hepatitis B, and Cancer Immunotherapy ATLANTA, G A
GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates Progress in Multiple Vaccine Programs Including HIV, Zika, Lassa Fever, Malaria, Hepatitis B, and Cancer Immunotherapy ATLANTA, GA, November 9, 2017 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotec
Read more →GOVXGeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer ATLANTA
GeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer ATLANTA, GA, August 7, 2017 - GeoVax Labs, Inc. (OTCQB: GOVX), a
Read more →GOVXGeoVax Reports 2017 First Quarter Financial Results and Development Program Updates Zika Vaccine Demonstrates 100% Protection in Preclinical Lethal Challenge Model Malaria Vaccine Development Initiated with The Burnet In
GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates Zika Vaccine Demonstrates 100% Protection in Preclinical Lethal Challenge Model Malaria Vaccine Development Initiated with The Burnet Institute HIV Vaccine Continues Successful Progress ATLAN
Read more →GOVXGeoVax Reports 2016 Year-End Financial Results ATLANTA, GA
GeoVax Reports 2016 Year-End Financial Results ATLANTA, GA, March 24, 2017 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2
Read more →GOVXGeoVax Reports 2016 Third Quarter Financial Results and Provides Corporate Update Updates on Multiple Vaccine Programs Including Zika, HIV, Hemorrhagic Fevers, and Cancer ATLANTA, GA, November 11 , 2016 - GeoVax Labs, In
GeoVax Reports 2016 Third Quarter Financial Results and Provides Corporate Update Updates on Multiple Vaccine Programs Including Zika, HIV, Hemorrhagic Fevers, and Cancer ATLANTA, GA, November 11, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human
Read more →GOVXGeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update Ongoing Vaccine Programs in Zika, HIV, Hemorrhagic Fevers, Hepatitis B and Cancer ATLANTA, GA, August 5 , 2016 - GeoVax Labs, Inc. (OTCQB
GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update Ongoing Vaccine Programs in Zika, HIV, Hemorrhagic Fevers, Hepatitis B and Cancer ATLANTA, GA, August 5, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines
Read more →GOVXGeoVax Reports 2016 First Quarter Financial Results ATLANTA, GA
GeoVax Reports 2016 First Quarter Financial Results ATLANTA, GA, May 4, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2016. GeoVax reported a net loss for the
Read more →GOVXGeoVax Reports 2015 Year-End Financial Results And Provides Corporate Update ATLANTA, GA
GeoVax Reports 2015 Year-End Financial Results And Provides Corporate Update ATLANTA, GA, March 16, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for
Read more →GOVXGeoVax to Develop Vaccine Against Zika Virus Collaboration with University of Georgia infectious disease researchers will speed development ATLANTA, GA, February 3 , 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnolog
GeoVax to Develop Vaccine Against Zika Virus Collaboration with University of Georgia infectious disease researchers will speed development ATLANTA, GA, February 3, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that i
Read more →GOVXGeoVax Begins Oncology Immunotherapy Program GeoVax to Apply its MVA-VLP Vaccine Technology to Cancer Immunotherapy Collaborative Research Agreement Signed with University of Pittsburgh ATLANTA, GA, December 8 , 2015 - G
GeoVax Begins Oncology Immunotherapy Program GeoVax to Apply its MVA-VLP Vaccine Technology to Cancer Immunotherapy Collaborative Research Agreement Signed with University of Pittsburgh ATLANTA, GA, December 8, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company de
Read more →GOVXGeoVax Reports 2015 Third Quarter Financial Results ATLANTA, GA
GeoVax Reports 2015 Third Quarter Financial Results ATLANTA, GA, November 12, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines for HIV, Ebola virus and other infectious diseases using its novel platform technology, announced its financial
Read more →GOVXGeoVax Reports 2015 Second Quarter Financial Results and Provides Corporate Update Ebola Vaccine Preclinical Data to be Released Late Summer Clade B HIV Vaccine Clinical Trial (HVTN 114) on Track to Start in Late 2015 HI
GeoVax Reports 2015 Second Quarter Financial Results and Provides Corporate Update Ebola Vaccine Preclinical Data to be Released Late Summer Clade B HIV Vaccine Clinical Trial (HVTN 114) on Track to Start in Late 2015 HIV Vaccine Program for Africa Advancing ATLANTA, GA, Aug
Read more →GOVXGeoVax Reports 2015 First Quarter Financial Results And Provides Corporate Update Ebola/Marburg Vaccine Program Advances with NIH Collaboration; HIV Vaccine Program Proceeding Toward Pivotal Trial ATLANTA, GA, May 13 , 2
GeoVax Reports 2015 First Quarter Financial Results And Provides Corporate Update Ebola/Marburg Vaccine Program Advances with NIH Collaboration; HIV Vaccine Program Proceeding Toward Pivotal Trial ATLANTA, GA, May 13, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology co
Read more →GOVXGeoVax Appoints Industry Veteran to its Board of Directors Randal D. Chase, Ph.D. Brings Extensive Vaccine Background to GeoVax ATLANTA, GA, March 2 3 , 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company dev
GeoVax Appoints Industry Veteran to its Board of Directors Randal D. Chase, Ph.D. Brings Extensive Vaccine Background to GeoVax ATLANTA, GA, March 23, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg
Read more →GOVXGeoVax Reports 2014 Year-End Financial Results Progress Report Outlined on Ebola/Marburg and HIV Vaccine Programs ATLANTA, GA
GeoVax Reports 2014 Year-End Financial Results Progress Report Outlined on Ebola/Marburg and HIV Vaccine Programs ATLANTA, GA, March 20, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, tod
Read more →GOVXGeoVax Announces Equity Financing of Up to $6 Million Funds to be Used to Advance the Company' s Innovative Vaccine Technology and Move its Ebola Vaccine Candidates t oward Human Clinical Testing ATLANTA, GA, February 25
GeoVax Announces Equity Financing of Up to $6 Million Funds to be Used to Advance the Company's Innovative Vaccine Technology and Move its Ebola Vaccine Candidates toward Human Clinical Testing ATLANTA, GA, February 25, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology c
Read more →GOVXGeoVax Reports 2014 Third Quarter Financial Results ATLANTA, G A
GeoVax Reports 2014 Third Quarter Financial Results ATLANTA, GA, November 11, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced financial results and recent developmen
Read more →GOVXGeoVax Announces Initiation of Ebola Vaccine Development Program GeoVax Developing Vaccines for Epidemic Response as Well as for Routine Immunization ATLANTA, GA
GeoVax Announces Initiation of Ebola Vaccine Development Program GeoVax Developing Vaccines for Epidemic Response as Well as for Routine Immunization ATLANTA, GA, October 2, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines us
Read more →GOVXGeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update ATLANTA, G A .
GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update ATLANTA, GA., August 7, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the three and six mo
Read more →GOVXGeoVax Reports 2014 First Quarter Financial Results And Provides Corporate Update ATLANTA, GA
GeoVax Reports 2014 First Quarter Financial Results And Provides Corporate Update ATLANTA, GA, May 1, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, announced its financial results for the three months ended March 31, 2014 and prov
Read more →About GeoVax Labs, Inc.
Headquarters1955 LAKE PARK DRIVE, SMYRNA, GA
BIOPHARMAWATCH ELITE PLUS
Trade the next GOVX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime